Lord, Abbett & Co’s Immunovant IMVT Stock Holding History

Lord, Abbett & Co’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-629,882	Closed	-$20.4M	–	552
2024 Q1	$20.4M	Sell	629,882 -1,517	-0.2%	-$55.3K	0.07%	332
2023 Q4	$26.6M	Buy	+631,399	New	+$23.2M	0.09%	276

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Lord, Abbett & Co's IMVT Position: Q2 2024 in Review

Lord, Abbett & Co sold out of Immunovant (IMVT) in Q2 2024, closing a stake of 629,882 shares — an estimated $20.4M sold.

Lord, Abbett & Co first reported a position in IMVT in Q4 2023 and held it in 2 quarters. The position peaked at $26.6M in Q4 2023. 197 funds tracked by Wall St. Rank hold IMVT as of Q2 2024.

Lord, Abbett & Co reported no remaining Immunovant position as of Q2 2024 after selling out during the quarter.
Lord, Abbett & Co sold 629,882 Immunovant shares in Q2 2024, an estimated $20.4M.
Lord, Abbett & Co first reported a position in Immunovant in Q4 2023 and held it in 2 quarters.
Lord, Abbett & Co's Immunovant position peaked at $26.6M in Q4 2023.
197 funds tracked by Wall St. Rank held Immunovant as of Q2 2024.

Based on Lord, Abbett & Co's 13F filing for Q2 2024, filed 14 Aug 2024.